TO READ THIS STORY - you must have a paid subscription to Technology Review OR you can purchase special archive reading credits here. Choose from these great offers below.

I'm a paid subscriber please
log me in

I want to purchase this article for
only 99¢
(requires login)

I want to purchase five articles for
only $3.99
(requires login)

I want to buy
1 Year TOTAL Access for
only $24.95
(requires login)

Please note: Click here if you are currently a Technology Review print or digital subscriber and do not have access to this article.

Click here if you are an MIT alum and do not have access to this article.

December 2001

Medicine's New Millennium

New information about genes and proteins promises precise diagnostics and drugs. Millennium Pharmaceuticals' CEO is at the forefront of this medical transformation.

By Technology Review

With his casual clothes and slightly disheveled hair, Mark Levin doesn't stand out in the scientist-infested Cambridge, MA, neighborhood that's home to his company Millennium Pharmaceuticals. In biotech circles, however, the 51-year-old Millennium CEO and cofounder is known to be somewhat of a character.

Select from the choices above
to read the entire article.

Customer Service

Magazine Services

•	Subscription FAQ
•	Pay Your Bill
•	Renew Your Subscription
•	Change Your Address
•	Check Your Start/Expire Issue
•	Feedback
•	Buy a Back Issue
•	Permissions/Reprints
•	Cancel Your Subscription
•	Digital Subscription Customer Service